Personalised mRNA cancer vaccine cuts melanoma recurrence by 42%

Adding a personalised mRNA cancer vaccine to immunotherapy after surgery for high-risk melanoma cut the risk of recurrence or death by 42%, according to the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026. Patients received the vaccine, intismeran autogene, together with pembrolizumab, and were compared with those given pembrolizumab alone.